RESUMEN
Cpl-1, an endolysin derived from Cp-1 phage has been found to be effective in a number of in-vitro and in-vivo pneumococcal infection models. However its lower bioavailability under in-vivo conditions limits its applicability as therapeutic agent. In this study, Cpl-1 loaded chitosan nanoparticles were set up in order to develop a novel therapeutic delivery system to counter antibiotic resistant S. pneumoniae infections. Interactions of chitosan and Cpl-1 were studied by in-silico docking analysis. Chitosan nanoparticles and Cpl-1 loaded chitosan nanoparticles were prepared by using ionic gelation method and the process was optimized by varying chitosan:TPP ratio, pH, stirring time, stirring rate and Cpl-1 concentration. Chitosan nanoparticles and Cpl-1 loaded chitosan nanoparticles were characterized to ascertain successful formation of nanoparticles and entrapment of Cpl-1 into nanoparticles. Chitosan nanoparticles and Cpl-1 loaded nanoparticles were also evaluated for nanoparticle yield, entrapment efficiency, in-vitro release, stability, structural integrity of Cpl-1, in-vitro bioassay, swelling studies, in-vitro biodegradation and heamolysis studies. Mucoadhesion behavior of chitosan nanoparticles and Cpl-1 loaded nanoparticles was explored using mucous glycoprotein assay and ex-vivo mucoadhesion assay, both preparations exhibited their mucoadhesive nature. Cellular cytotoxicity and immune stimulation studies revealed biocompatible nature of nanoparticles. The results of this study confirm that chitosan nanoparticles are a promising biocompatible candidate for Cpl-1 delivery with a significant potential to increase bioavailability of enzyme that in turn can increase its in-vivo half life to treat S. pneumoniae infections.
Asunto(s)
Portadores de Fármacos/química , Composición de Medicamentos/métodos , Endopeptidasas/administración & dosificación , Nanopartículas/química , Neumonía Neumocócica/tratamiento farmacológico , Proteínas Virales/administración & dosificación , Células A549 , Administración Intranasal , Animales , Bacteriófagos/enzimología , Disponibilidad Biológica , Quitosano/química , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/farmacocinética , Evaluación Preclínica de Medicamentos , Liberación de Fármacos , Endopeptidasas/química , Endopeptidasas/aislamiento & purificación , Endopeptidasas/farmacocinética , Estudios de Factibilidad , Semivida , Humanos , Masculino , Ensayo de Materiales , Ratones , Simulación del Acoplamiento Molecular , Neumonía Neumocócica/inmunología , Neumonía Neumocócica/microbiología , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/química , Proteínas Recombinantes/aislamiento & purificación , Proteínas Recombinantes/farmacocinética , Streptococcus pneumoniae/aislamiento & purificación , Streptococcus pneumoniae/virología , Proteínas Virales/química , Proteínas Virales/aislamiento & purificación , Proteínas Virales/farmacocinéticaRESUMEN
BACKGROUND: Streptococcus pneumoniae is a major causative agent in community-acquired pneumonia and sepsis. Overwhelming lung inflammation during pneumococcal pneumonia may hamper lung function. Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk), a key signaling protein controlling the activation of various immune cells, including macrophages and neutrophils. The aim of this study was to determine whether ibrutinib treatment ameliorates acute lung inflammation during pneumococcal pneumonia. METHODS: Mice were treated orally with ibrutinib and the effect on acute pulmonary inflammation elicited by the gram-positive bacterial cell wall component lipoteichoic acid (LTA) and during ceftriaxone-treated pneumococcal pneumonia was assessed. RESULTS: Treatment with ibrutinib prior to and after intranasal LTA instillation reduced alveolar macrophage activation, neutrophil influx, cytokine release and plasma leakage into the lung. Postponed treatment with ibrutinib supplementing antibiotic therapy during ongoing pneumococcal pneumonia did not impair bacterial killing in lung, blood and spleen. In this setting, ibrutinib reduced alveolar macrophage and systemic neutrophil activation and substantially diminished further monocyte and neutrophil influx in the lung. In vitro, ibrutinib inhibited macrophage TNF secretion and neutrophil activation upon LTA and pneumococcal stimulation. CONCLUSIONS: Taken together, these data indicate that the Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses during acute pulmonary inflammation evoked by LTA and antibiotic-treated pneumococcal pneumonia and suggest that ibrutinib has the potential to inhibit ongoing lung inflammation in an acute infectious setting.
Asunto(s)
Agammaglobulinemia Tirosina Quinasa/antagonistas & inhibidores , Antiinflamatorios/uso terapéutico , Neumonía Neumocócica/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/uso terapéutico , Pirazoles/uso terapéutico , Pirimidinas/uso terapéutico , Adenina/análogos & derivados , Animales , Antibacterianos/uso terapéutico , Líquido del Lavado Bronquioalveolar/citología , Ceftriaxona/uso terapéutico , Lipopolisacáridos , Pulmón/efectos de los fármacos , Pulmón/inmunología , Masculino , Ratones Endogámicos C57BL , Ratones Noqueados , Células Mieloides/efectos de los fármacos , Células Mieloides/inmunología , Piperidinas , Neumonía Neumocócica/inmunología , Ácidos TeicoicosRESUMEN
BACKGROUND: The immunomodulatory effects of statins on vaccine response remain uncertain. Therefore, the objective of this study was to determine if atorvastatin enhances pneumococcal-specific antibody titer following 23-valent pneumococcal polysaccharide vaccination. METHODS: Double-blind, placebo-controlled, single-center randomized clinical trial entitled StatVax. Subjects were enrolled between June and July 2014 and followed up through September 2014. 33 healthy volunteers signed informed consent after volunteer sampling. 11 participants were excluded; 22 healthy volunteers without prior pneumococcal vaccination were enrolled and completed the study. Participants were randomized to receive a 28-day course of 40â¯mg atorvastatin (nâ¯=â¯12) or matching lactose placebo (nâ¯=â¯10). On day 7 of treatment, Pneumovax 23 was administered intramuscularly. The primary outcome was fold change in total pneumococcal-specific antibody titer determined by a ratio of post-vaccination titer over baseline titer. Secondary outcomes included serotype-specific pneumococcal antibody titer, seroconversion, complete blood counts (CBC), erythrocyte sedimentation rate (ESR), and serum cytokine analysis. RESULTS: Of the 22 randomized patients (mean age, 23.86; SD, 4.121; 11 women [50%]), 22 completed the trial. Total anti-pneumococcal antibody titer in the atorvastatin group went from a baseline mean of 32.58 (SD, 15.96) to 147.7 (SD, 71.52) µg/mL at 21â¯days post-vaccination while titer in the placebo group went from a mean of 30.81 (SD, 13.04) to 104.4 (SD, 45) µg/mL. When comparing fold change between treatment groups, there was a significant increase in fold change of total anti-pneumococcal antibody titer in the atorvastatin group compared to the placebo group (2-way ANOVA, pâ¯=â¯.0177). CONCLUSIONS: Atorvastatin enhances antigen-specific primary humoral immune response to a T cell-independent pneumonia vaccination. Pending confirmation by larger cohort studies of target populations, peri-vaccination conventional doses of statins can become a novel adjuvant for poorly-immunogenic polysaccharide-based vaccines. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02097589.
Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Anticuerpos Antibacterianos/sangre , Anticolesterolemiantes/inmunología , Atorvastatina/inmunología , Inmunidad Humoral , Vacunas Neumococicas/inmunología , Adulto , Formación de Anticuerpos , Anticolesterolemiantes/administración & dosificación , Atorvastatina/administración & dosificación , Citocinas/sangre , Método Doble Ciego , Femenino , Voluntarios Sanos , Humanos , Masculino , Vacunas Neumococicas/administración & dosificación , Neumonía Neumocócica/inmunología , Neumonía Neumocócica/prevención & control , Streptococcus pneumoniae , Vacunación , Adulto JovenRESUMEN
Despite the availability of vaccines, Streptococcus pneumoniae remains a leading cause of life-threatening infections, such as pneumonia, bacteremia and meningitis. Polymorphonuclear leukocytes (PMNs) are a key determinant of disease course, because optimal host defense requires an initial robust pulmonary PMN response to control bacterial numbers followed by modulation of this response later in infection. The elderly, who manifest a general decline in immune function and higher basal levels of inflammation, are at increased risk of developing pneumococcal pneumonia. Using an aged mouse infection model, we previously showed that oral supplementation with the alpha-tocopherol form of vitamin E (α-Toc) decreases pulmonary inflammation, in part by modulating neutrophil migration across lung epithelium into alveolar spaces, and reverses the age-associated decline in resistance to pneumococcal pneumonia. The objective of this study was to test the effect of α-Toc on the ability of neutrophils isolated from young (22-35 years) or elderly (65-69 years) individuals to migrate across epithelial cell monolayers in response to S. pneumoniae and to kill complement-opsonized pneumococci. We found that basal levels of pneumococcal-induced transepithelial migration by PMNs from young or elderly donors were indistinguishable, suggesting that the age-associated exacerbation of pulmonary inflammation is not due to intrinsic properties of PMNs of elderly individuals but rather may reflect the inflammatory milieu of the aged lung. Consistent with its anti-inflammatory activity, α-Toc treatment diminished PMN migration regardless of donor age. Unexpectedly, unlike previous studies showing poor killing of antibody-opsonized bacteria, we found that PMNs of elderly donors were more efficient at killing complement-opsonized bacteria ex vivo than their younger counterparts. We also found that the heightened antimicrobial activity in PMNs from older donors correlated with increased activity of neutrophil elastase, a serine protease that is required to kill pneumococci. Notably, incubation with α-Toc increased PMN elastase activity from young donors and boosted their ability to kill complement-opsonized pneumococci. These findings demonstrate that α-Toc is a potent modulator of PMN responses and is a potential nutritional intervention to combat pneumococcal infection.
Asunto(s)
Elastasa de Leucocito/efectos de los fármacos , Neutrófilos/efectos de los fármacos , Neutrófilos/inmunología , Neutrófilos/metabolismo , Neumonía Neumocócica/inmunología , Streptococcus pneumoniae/inmunología , alfa-Tocoferol/farmacología , Administración Oral , Adulto , Factores de Edad , Anciano , Animales , Antiinfecciosos/farmacología , Catepsina G/efectos de los fármacos , Movimiento Celular/efectos de los fármacos , Movimiento Celular/inmunología , Modelos Animales de Enfermedad , Epitelio/inmunología , Epitelio/microbiología , Humanos , Inflamación/inmunología , Pulmón/inmunología , Pulmón/microbiología , Ratones , Fagocitosis , Neumonía Neumocócica/microbiología , Serina Proteasas/efectos de los fármacos , Streptococcus pneumoniae/patogenicidad , Vitamina E/química , alfa-Tocoferol/administración & dosificación , alfa-Tocoferol/químicaRESUMEN
Pneumococcal disease continues to be a medical need even with very effective vaccines on the market. Globally, there are extensive research efforts to improve serotype coverage with novel vaccines; therefore, conducting preclinical studies in different animal models becomes essential. The work presented herein focuses on evaluating a 15-valent pneumococcal conjugate vaccine (PCV15) in mice. Initially we evaluated several doses of PCV15 in Balb/c mice. The optimal vaccine dose was determined to be 0.4µg per pneumococcal polysaccharide (PS) (0.8µg of 6B) for subsequent studies. This PS dose was chosen for PCV evaluation in mice based on antibody levels determined by multiplexed electrochemiluminescent (ECL) assays, T-cell responses following in vitro stimulation with CRM197 peptides and protection from pneumococcal challenge. We then selected four mouse strains for evaluation: Balb/c, C3H/HeN, CD1 and Swiss Webster (SW), immunized with PCV15 by either intraperitoneal (IP) or intramuscular (IM) routes. We assessed IgG responses by ECL assays and functional antibody activity by multiplexed opsonophagocytic assays (MOPA). Every mouse strain evaluated responded to all 15 serotypes contained in the vaccine. Mice tended to have lower responses to serotypes 6B, 23F and 33F. The IP route of immunization resulted in higher antibody titers for most serotypes in Balb/c, C3H and SW. CD1 mice tended to respond similarly for most serotypes, regardless of route of immunization. Similar trends were observed with the four mouse strains when evaluating functional antibody activity. Given the differences in antibody responses based on mouse strain and route of immunization, it is critical to evaluate pneumococcal vaccines in multiple animal models to determine the optimal formulation before moving to clinical trials.
Asunto(s)
Anticuerpos Antibacterianos/biosíntesis , Inmunoglobulina G/biosíntesis , Vacunas Neumococicas/administración & dosificación , Neumonía Neumocócica/prevención & control , Streptococcus pneumoniae/efectos de los fármacos , Vacunación , Animales , Proteínas Bacterianas/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta Inmunológica , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Inyecciones Intramusculares , Inyecciones Intraperitoneales , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C3H , Ratones Endogámicos , Vacunas Neumococicas/síntesis química , Neumonía Neumocócica/inmunología , Neumonía Neumocócica/microbiología , Polisacáridos Bacterianos/administración & dosificación , Polisacáridos Bacterianos/química , Polisacáridos Bacterianos/inmunología , Serogrupo , Especificidad de la Especie , Streptococcus pneumoniae/química , Streptococcus pneumoniae/inmunología , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , Vacunas ConjugadasRESUMEN
BACKGROUND: The pneumococcal urinary antigen test (PUAT) is commonly used for the etiological diagnosis of community-acquired pneumonia (CAP) and can be useful for targeting pathogen-directed therapy. OBJECTIVES: The aim of our study was to evaluate the diagnostic yield of the PUAT and the impact of a positive PUAT result on antibiotic treatment in patients with CAP in a clinical non-research setting. METHODS: Adults hospitalized with CAP between January 2005 and November 2007 were studied retrospectively. All patients were tested by PUAT. The sensitivity of the PUAT was determined and changes in antibiotic therapy were assessed. RESULTS: A total of 681 patients with CAP were included. The microorganism most frequently identified was Streptococcus pneumoniae. It was found in 95 (14.0%) patients, and the PUAT increased the diagnostic yield to a total of 184 (27.0%) patients. The S. pneumoniae antigen was detected in 37 of 55 patients with definitive pneumococcal pneumonia (67.3%). Pneumococcal urinary antigen was positive in 56 of 95 pneumococcal cases (definite and probable), resulting in an overall test sensitivity of 59.0%. Positive results of the PUAT led physicians to narrow the spectrum of antibiotic treatment in 69 (45.1%) patients. CONCLUSIONS: The PUAT is a useful method for early detection of S. pneumoniae in patients with CAP, but the test was less sensitive in this clinical setting than prospective studies indicated. The PUAT results led physicians to narrow the spectrum of antibiotic treatment in approximately half of the relevant cases, which limited the impact of a positive PUAT.
Asunto(s)
Antibacterianos/inmunología , Antígenos Bacterianos/orina , Infecciones Comunitarias Adquiridas/inmunología , Neumonía Neumocócica/inmunología , Streptococcus pneumoniae/inmunología , Anciano , Anciano de 80 o más Años , Antibacterianos/uso terapéutico , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Infecciones Comunitarias Adquiridas/etiología , Infecciones Comunitarias Adquiridas/microbiología , Femenino , Humanos , Masculino , Pruebas de Sensibilidad Microbiana/estadística & datos numéricos , Persona de Mediana Edad , Países Bajos/epidemiología , Neumonía Neumocócica/tratamiento farmacológico , Neumonía Neumocócica/microbiología , Neumonía Neumocócica/orina , Estudios Retrospectivos , Streptococcus pneumoniae/efectos de los fármacos , Streptococcus pneumoniae/aislamiento & purificaciónRESUMEN
Patients with inflammatory bowel disease (IBD) do not receive routine preventative care at the same rate as general medical patients. This patient population is at increased risk of vaccine preventable illness such as influenza and pneumococcal pneumonia. This review will discuss health maintenance needs and preventative care issues in patients with IBD.
Asunto(s)
Neoplasias Colorrectales/diagnóstico , Inmunosupresores/efectos adversos , Enfermedades Inflamatorias del Intestino/terapia , Medicina Preventiva/métodos , Vacunación/métodos , Conservadores de la Densidad Ósea/uso terapéutico , Varicela/etiología , Varicela/inmunología , Varicela/prevención & control , Vacuna contra la Varicela/uso terapéutico , Depresión/diagnóstico , Depresión/terapia , Manejo de la Enfermedad , Detección Precoz del Cáncer/métodos , Hepatitis Viral Humana/etiología , Hepatitis Viral Humana/inmunología , Hepatitis Viral Humana/prevención & control , Herpes Zóster/etiología , Herpes Zóster/inmunología , Herpes Zóster/prevención & control , Vacuna contra el Herpes Zóster/uso terapéutico , Humanos , Huésped Inmunocomprometido , Vacunas contra la Influenza/uso terapéutico , Gripe Humana/etiología , Gripe Humana/inmunología , Gripe Humana/prevención & control , Sarampión/etiología , Sarampión/inmunología , Sarampión/prevención & control , Vacuna contra el Sarampión-Parotiditis-Rubéola/uso terapéutico , Meningitis Meningocócica/etiología , Meningitis Meningocócica/inmunología , Meningitis Meningocócica/prevención & control , Vacunas Meningococicas/uso terapéutico , Paperas/etiología , Paperas/inmunología , Paperas/prevención & control , Osteoporosis/diagnóstico por imagen , Osteoporosis/tratamiento farmacológico , Infecciones por Papillomavirus/etiología , Infecciones por Papillomavirus/inmunología , Infecciones por Papillomavirus/prevención & control , Vacunas contra Papillomavirus/uso terapéutico , Vacunas Neumococicas/uso terapéutico , Neumonía Neumocócica/etiología , Neumonía Neumocócica/inmunología , Neumonía Neumocócica/prevención & control , Rubéola (Sarampión Alemán)/etiología , Rubéola (Sarampión Alemán)/inmunología , Rubéola (Sarampión Alemán)/prevención & control , Cese del Hábito de Fumar , Vacunas contra Hepatitis Viral/uso terapéutico , Vitamina D/uso terapéutico , Deficiencia de Vitamina D/diagnósticoRESUMEN
Immunization with the pneumococcal proteins pneumolysin (Ply), choline binding protein A (CbpA), or pneumococcal surface protein A (PspA) elicits protective responses against invasive pneumococcal disease in animal models. In this study, we used different mouse models to test the efficacy of a variety of multivalent protein-based vaccines that comprised various combinations of full-length or peptide regions of the immunogens Ply, CbpA, or PspA: Ply toxoid with the L460D substitution (referred to herein as L460D); L460D fused with protective peptide epitopes from CbpA (YPT-L460D-NEEK [YLN]); L460D fused with the CD2 peptide containing the proline-rich region (PRR) of PspA (CD2-L460D); a combination of L460D and H70 (L460D+H70), a slightly larger PspA-derived peptide containing the PRR and the SM1 region; H70+YLN; and other combinations. Each mouse was immunized either intraperitoneally (i.p.) or subcutaneously (s.c.) with three doses (at 2-week intervals) of the various antigen combinations in alum adjuvant and then challenged in mouse models featuring different infection routes with multiple Streptococcus pneumoniae strains. In the i.p. infection sepsis model, H70+YLN consistently provided significant protection against three different challenge strains (serotypes 1, 2, and 6A); the CD2+YLN and H70+L460D combinations also elicited significant protection. Protection against intravenous (i.v.) sepsis (type 3 and 6A challenge strains) was largely dependent on PspA-derived antigen components, and the most protection was elicited by H70 with or without L460D or YLN. In a type 4 intratracheal (i.t.) challenge model that results in progression to meningitis, antigen combinations that contained YLN elicited the strongest protection. Thus, the trivalent antigen combination of H70+YLN elicited the strongest and broadest protection in diverse pneumococcal challenge models.
Asunto(s)
Proteínas Bacterianas/inmunología , Infecciones Neumocócicas/prevención & control , Vacunas Neumococicas/inmunología , Sepsis/prevención & control , Streptococcus pneumoniae/inmunología , Estreptolisinas/inmunología , Animales , Proteínas Bacterianas/genética , Modelos Animales de Enfermedad , Epítopos/genética , Epítopos/inmunología , Esquemas de Inmunización , Inmunoglobulina G/sangre , Meningitis Neumocócica/inmunología , Meningitis Neumocócica/microbiología , Meningitis Neumocócica/prevención & control , Ratones Endogámicos BALB C , Infecciones Neumocócicas/inmunología , Vacunas Neumococicas/administración & dosificación , Vacunas Neumococicas/genética , Neumonía Neumocócica/inmunología , Neumonía Neumocócica/microbiología , Neumonía Neumocócica/prevención & control , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/inmunología , Sepsis/microbiología , Streptococcus pneumoniae/clasificación , Toxoides/inmunología , Vacunación , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/inmunologíaRESUMEN
Strategies for the treatment of bacterial pneumonia beyond traditional antimicrobial therapy have been limited. The recently discovered novel genus of lipid mediators, coined "specialized proresolving mediators" (SPMs), which orchestrate clearance of recruited leukocytes and restore epithelial barrier integrity, have offered new insight into the resolution of inflammation. We performed lipid mediator (LM) metabololipidomic profiling and identification of LMs on peripheral blood leukocytes and plasma from a baboon model of Streptococcus pneumoniae pneumonia. Leukocytes and plasma were isolated from whole blood of S. pneumoniae-infected (n = 5-6 per time point) and control, uninfected baboons (n = 4 per time point) at 0, 24, 48, and 168 hours. In a subset of baboons with pneumonia (n = 3), we administered inhaled carbon monoxide (CO) at 48 hours (200-300 ppm for 60-90 min). Unstimulated leukocytes from control animals produced a proresolving LM signature with elevated resolvins and lipoxins. In contrast, serum-treated, zymosan-stimulated leukocytes and leukocytes from baboons with S. pneumoniae pneumonia produced a proinflammatory LM signature profile with elevated leukotriene B4 and prostaglandins. Plasma from baboons with S. pneumoniae pneumonia also displayed significantly reduced LM-SPM levels, including eicosapentaenoic acid-derived E-series resolvins (RvE) and lipoxins. CO inhalation increased levels of plasma RvE and lipoxins relative to preexposure levels. These results establish the leukocyte and plasma LM profiles biosynthesized during S. pneumoniae pneumonia in baboons and provide evidence for pneumonia-induced dysregulation of these proresolution programs. Moreover, these SPM profiles are partially restored with inhaled low-dose CO and SPM, which may shorten the time to pneumonia resolution.
Asunto(s)
Monóxido de Carbono/administración & dosificación , Factores Inmunológicos/administración & dosificación , Lípidos/sangre , Neumonía Neumocócica/sangre , Administración por Inhalación , Animales , Evaluación Preclínica de Medicamentos , Leucocitos Mononucleares/metabolismo , Leucotrieno B4/sangre , Metabolismo de los Lípidos , Masculino , Metaboloma , Papio , Neumonía Neumocócica/tratamiento farmacológico , Neumonía Neumocócica/inmunología , Streptococcus pneumoniae/inmunologíaRESUMEN
Although the importance of alveolar macrophages for host immunity during early Streptococcus pneumoniae lung infection is well established, the contribution and relative importance of other innate immunity mechanisms and of bacterial factors are less clear. We have used a murine model of S. pneumoniae early lung infection with wild-type, unencapsulated, and para-amino benzoic acid auxotroph mutant TIGR4 strains to assess the effects of inoculum size, bacterial replication, capsule, and alveolar macrophage-dependent and -independent clearance mechanisms on bacterial persistence within the lungs. Alveolar macrophage-dependent and -independent (calculated indirectly) clearance half-lives and bacterial replication doubling times were estimated using a mathematical model. In this model, after infection with a high-dose inoculum of encapsulated S. pneumoniae, alveolar macrophage-independent clearance mechanisms were dominant, with a clearance half-life of 24 min compared to 135 min for alveolar macrophage-dependent clearance. In addition, after a high-dose inoculum, successful lung infection required rapid bacterial replication, with an estimated S. pneumoniae doubling time of 16 min. The capsule had wide effects on early lung clearance mechanisms, with reduced half-lives of 14 min for alveolar macrophage-independent and 31 min for alveolar macrophage-dependent clearance of unencapsulated bacteria. In contrast, with a lower-dose inoculum, the bacterial doubling time increased to 56 min and the S. pneumoniae alveolar macrophage-dependent clearance half-life improved to 42 min and was largely unaffected by the capsule. These data demonstrate the large effects of bacterial factors (inoculum size, the capsule, and rapid replication) and alveolar macrophage-independent clearance mechanisms during early lung infection with S. pneumoniae.
Asunto(s)
Inmunidad Innata , Pulmón/inmunología , Macrófagos Alveolares/inmunología , Modelos Estadísticos , Neumonía Neumocócica/inmunología , Streptococcus pneumoniae/inmunología , Ácido 4-Aminobenzoico/metabolismo , Animales , Cápsulas Bacterianas/inmunología , Carga Bacteriana/inmunología , Femenino , Semivida , Pulmón/microbiología , Pulmón/patología , Macrófagos Alveolares/microbiología , Macrófagos Alveolares/patología , Masculino , Ratones , Ratones Endogámicos , Mutación , Fagocitosis , Neumonía Neumocócica/microbiología , Neumonía Neumocócica/patología , Índice de Severidad de la Enfermedad , Streptococcus pneumoniae/genética , Streptococcus pneumoniae/crecimiento & desarrollo , Factores de TiempoRESUMEN
Streptococcus pneumoniae infections are an important cause of morbidity and mortality in older patients. Uncontrolled neutrophil-driven pulmonary inflammation exacerbates this disease. To test whether the α-tocopherol (α-Toc) form of vitamin E, a regulator of immunity, can modulate neutrophil responses as a preventive strategy to mitigate the age-associated decline in resistance to S. pneumoniae, young (4 mo) and old (22-24 mo) C57BL/6 mice were fed a diet containing 30-PPM (control) or 500-PPM (supplemented) α-Toc for 4 wk and intratracheally infected with S. pneumoniae. Aged mice fed a control diet were exquisitely more susceptible to S. pneumoniae than young mice. At 2 d postinfection, aged mice suffered 1000-fold higher pulmonary bacterial burden, 2.2-fold higher levels of neutrophil recruitment to the lung, and a 2.25-fold higher rate of lethal septicemia. Strikingly, α-Toc supplementation of aged mice resulted in a 1000-fold lower bacterial lung burden and full control of infection. This α-Toc-induced resistance to pneumococcal challenge was associated with a 2-fold fewer pulmonary neutrophils, a level comparable to S. pneumoniae-challenged, conventionally fed young mice. α-Toc directly inhibited neutrophil egress across epithelial cell monolayers in vitro in response to pneumococci or hepoxilin-A3, an eicosanoid required for pneumococcus-elicited neutrophil trans-epithelial migration. α-Toc altered expression of multiple epithelial and neutrophil adhesion molecules involved in migration, including CD55, CD47, CD18/CD11b, and ICAM-1. These findings suggest that α-Toc enhances resistance of aged mice to bacterial pneumonia by modulating the innate immune response, a finding that has potential clinical significance in combating infection in aged individuals through nutritional intervention.
Asunto(s)
Susceptibilidad a Enfermedades/inmunología , Infiltración Neutrófila/efectos de los fármacos , Infiltración Neutrófila/inmunología , Neumonía Neumocócica/inmunología , Streptococcus pneumoniae/inmunología , alfa-Tocoferol/farmacología , Ácido 8,11,14-Eicosatrienoico/análogos & derivados , Ácido 8,11,14-Eicosatrienoico/farmacología , Factores de Edad , Animales , Moléculas de Adhesión Celular/genética , Moléculas de Adhesión Celular/metabolismo , Suplementos Dietéticos , Modelos Animales de Enfermedad , Resistencia a la Enfermedad/efectos de los fármacos , Resistencia a la Enfermedad/inmunología , Epitelio/efectos de los fármacos , Epitelio/inmunología , Expresión Génica , Masculino , Ratones , Neutrófilos/efectos de los fármacos , Neutrófilos/inmunología , Neutrófilos/metabolismo , Neumonía Neumocócica/patología , Migración Transendotelial y Transepitelial/efectos de los fármacos , Migración Transendotelial y Transepitelial/inmunología , alfa-Tocoferol/administración & dosificaciónRESUMEN
Pathomorphological changes in the organs of animals intranasally infected with Streptococcus pneumoniae were studied under conditions of immunotropic therapy added to antibiotic therapy. The pathomorphosis in the lungs, spleen, and thymus in animals treated with likopid, tinrostim, and roncoleukin was described. A positive time course of the pathological process in experimental animals in comparison with intact animals and animals receiving no immunotropic drugs was demonstrated.
Asunto(s)
Acetilmuramil-Alanil-Isoglutamina/análogos & derivados , Suplementos Dietéticos , Factores Inmunológicos/farmacología , Interleucina-2/farmacología , Pulmón/patología , Neumonía Neumocócica/tratamiento farmacológico , Acetilmuramil-Alanil-Isoglutamina/farmacología , Acetilmuramil-Alanil-Isoglutamina/uso terapéutico , Animales , Animales no Consanguíneos , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Compuestos Aza/farmacología , Compuestos Aza/uso terapéutico , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Infecciones Comunitarias Adquiridas/inmunología , Evaluación Preclínica de Medicamentos , Quimioterapia Combinada , Fluoroquinolonas , Factores Inmunológicos/uso terapéutico , Interleucina-2/uso terapéutico , Pulmón/efectos de los fármacos , Pulmón/microbiología , Ratones , Moxifloxacino , Neumonía Neumocócica/inmunología , Quinolinas/farmacología , Quinolinas/uso terapéutico , Bazo/inmunología , Bazo/patología , Streptococcus pneumoniaeRESUMEN
Rapamycin, a potent immunomodulatory drug, has shown promise in the amelioration of numerous age-associated diseases including cancer, Alzheimer's disease and cardiac hypertrophy. Yet the elderly, the population most likely to receive therapeutic rapamycin, are already at increased risk for infectious disease; thus concern exists that rapamycin may exacerbate age-associated immune dysfunctions and worsen infection outcomes. Herein, we examined the impact of enteric delivered rapamycin monotherapy (eRapa) on the susceptibility of aged (22-24month) C57BL/6 mice to Streptococcus pneumoniae, the leading bacterial cause of community-acquired pneumonia. Following challenge with S. pneumoniae, administration of eRapa conferred modest protection against mortality. Reduced mortality was the result of diminished lung damage rather than reduced bacterial burden. eRapa had no effect on basal levels of Interleukin (IL)-1α, IL-6, IL-10, IL-12p70, KC, Interferon-γ, Tumor necrosis factor α and Monocyte chemotactic protein-1 in whole lung homogenates or during pneumococcal pneumonia. Previously we have demonstrated that cellular senescence enhances permissiveness for bacterial pneumonia through increased expression of the bacterial ligands Laminin receptor (LR), Platelet-activating factor receptor (PAFr) and Cytokeratin 10 (K10). These proteins are co-opted by S. pneumoniae and other respiratory tract pathogens for host cell attachment during lung infection. UM-HET3 mice on eRapa had reduced lung cellular senescence as determined by levels of the senescence markers p21 and pRB, but not mH2A.1. Mice on eRapa also had marked reductions in PAFr, LR, and K10. We conclude that eRapa protected aged mice against pneumonia through reduced lung cellular senescence, which in turn, lowered bacterial ligand expression.
Asunto(s)
Antibacterianos/uso terapéutico , Neumonía Neumocócica/prevención & control , Sirolimus/uso terapéutico , Animales , Antibacterianos/administración & dosificación , Senescencia Celular/efectos de los fármacos , Citocinas/biosíntesis , Susceptibilidad a Enfermedades , Evaluación Preclínica de Medicamentos , Femenino , Pulmón/inmunología , Masculino , Ratones , Ratones Endogámicos C57BL , Neumonía Neumocócica/inmunología , Neumonía Neumocócica/microbiología , Neumonía Neumocócica/patología , Receptores Inmunológicos/metabolismo , Sirolimus/administración & dosificación , Streptococcus pneumoniae/aislamiento & purificación , Comprimidos RecubiertosRESUMEN
The existing reports on the role of ω-3 polyunsaturated fatty acids (PUFA) in infectious diseases are contradictory. The present study was conducted to evaluate the effect of sea-cod oil on the course of respiratory tract infection by Streptococcus pneumoniae in BALB/c mice. Animals were given enteral sea-cod oil for a period of 30 and 60 days and challenged intra-tracheally with S. pneumoniae D39 serotype 2. The survival of animals and various inflammatory parameters, i.e. myeloperoxidase (MPO), malondialdehyde (MDA), nitric oxide (NO) and leukotriene B(4) in the lung homogenates, were investigated. The inflammatory cytokines levels (IL-1ß, TNF-α and IL-10) were also determined. Continuous sea-cod oil supplementation for 60 days significantly improved survival among the animals. A significant reduction in the bacterial load in the lungs of sea-cod oil-fed animals compared to the controls was observed. As the disease progressed, the reduced bacterial colonisation correlated well with the histopathological observation. This was accompanied by a decrease in the production of inflammatory mediators and cytokines in the lung homogenates. However, not even a minor difference was seen in animals given sea-cod oil supplementation for 30 days duration; therefore, long-term treatment was required to attain an effect. Sea-cod oil supplementation modulated the host immune response and, thus, protected the host from ensuing inflammatory damage due to S. pneumoniae-mediated infection.
Asunto(s)
Ácidos Grasos Omega-3/administración & dosificación , Aceites de Pescado/administración & dosificación , Neumonía Neumocócica/tratamiento farmacológico , Streptococcus pneumoniae/aislamiento & purificación , Animales , Carga Bacteriana/efectos de los fármacos , Citocinas/análisis , Suplementos Dietéticos , Gadiformes , Mediadores de Inflamación/análisis , Leucotrieno B4/análisis , Pulmón/química , Pulmón/inmunología , Pulmón/microbiología , Malondialdehído/análisis , Ratones , Ratones Endogámicos BALB C , Óxido Nítrico/análisis , Peroxidasa/metabolismo , Neumonía Neumocócica/inmunología , Neumonía Neumocócica/metabolismo , Neumonía Neumocócica/microbiologíaRESUMEN
AIMS: A cost-effectiveness model was used to estimate the change in disease burden that might be expected if PCV7 was included as part of the routine 3-dose vaccination schedule in Sweden. METHODS: An economic model was populated with data from the main clinical PCV7 efficacy trials, demographic data from government sources, surveillance and epidemiologic data from the US and Nordic region, and average treatment costs, considering the impact of disease on the whole national population. RESULTS: The model estimated that PCV7 would prevent 18,856 cases of AOM, 684 of pneumonia, 86 of pneumococcal bacteraemia and 21 cases of pneumococcal meningitis in children <10 years, further 221 cases of IPD would be avoided in older children and adults and 397 cases of pneumonia in adults aged 18-39 years. Annually, 4 childhood (<10 years) deaths and 39 deaths in older children and adults would be prevented, resulting in an annual saving of 632 life years. The reduction of cost for the society was estimated to 27.9 (-205, +160) million SEK. The sensitivity analysis showed that it was most sensitive to the efficacy of the vaccine against AOM, the cost of managing infections and the incidence of all disease. CONCLUSION: This model demonstrates that implementing a universal vaccine programme in Sweden with PCV7 would be cost-effective with an estimated net reduction of costs for the society.
Asunto(s)
Infecciones Neumocócicas/inmunología , Infecciones Neumocócicas/prevención & control , Vacunas Neumococicas/economía , Vacunas Neumococicas/farmacología , Adolescente , Adulto , Anciano , Bacteriemia/epidemiología , Bacteriemia/inmunología , Bacteriemia/prevención & control , Niño , Preescolar , Análisis Costo-Beneficio , Vacuna Neumocócica Conjugada Heptavalente , Humanos , Inmunidad Colectiva , Lactante , Recién Nacido , Meningitis Neumocócica/epidemiología , Meningitis Neumocócica/inmunología , Meningitis Neumocócica/prevención & control , Persona de Mediana Edad , Modelos Económicos , Programas Nacionales de Salud/economía , Otitis Media/epidemiología , Otitis Media/inmunología , Otitis Media/prevención & control , Infecciones Neumocócicas/epidemiología , Neumonía Neumocócica/epidemiología , Neumonía Neumocócica/inmunología , Neumonía Neumocócica/prevención & control , Suecia/epidemiología , Adulto JovenRESUMEN
The adipocyte-derived hormone leptin is an important regulator of appetite and energy expenditure and is now appreciated for its ability to control innate and adaptive immune responses. We have reported previously that the leptin-deficient ob/ob mouse exhibited increased susceptibility to the Gram-negative bacterium Klebsiella pneumoniae. In this report we assessed the impact of chronic leptin deficiency, using ob/ob mice, on pneumococcal pneumonia and examined whether restoring circulating leptin to physiological levels in vivo could improve host defences against this pathogen. We observed that ob/ob mice, compared with wild-type (WT) animals, exhibited enhanced lethality and reduced pulmonary bacterial clearance following Streptococcus pneumoniae challenge. These impairments in host defence in ob/ob mice were associated with elevated levels of lung tumour necrosis factor (TNF)-alpha, macrophage inflammatory peptide (MIP)-2 [correction added after online publication 28 September 2007: definition of MIP corrected], prostaglandin E(2) (PGE(2)), lung neutrophil polymorphonuclear leukocyte (PMN) counts, defective alveolar macrophage (AM) phagocytosis and PMN killing of S. pneumoniae in vitro. Exogenous leptin administration to ob/ob mice in vivo improved survival and greatly improved pulmonary bacterial clearance, reduced bacteraemia, reconstituted AM phagocytosis and PMN H(2)O(2) production and killing of S. pneumoniae in vitro. Our results demonstrate, for the first time, that leptin improves pulmonary bacterial clearance and survival in ob/ob mice during pneumococcal pneumonia. Further investigations are warranted to determine whether there is a potential therapeutic role for this adipokine in immunocompromised patients.
Asunto(s)
Leptina/uso terapéutico , Pulmón/microbiología , Neumonía Neumocócica/tratamiento farmacológico , Streptococcus pneumoniae/patogenicidad , Animales , Bacteriemia/tratamiento farmacológico , Citocinas/biosíntesis , Susceptibilidad a Enfermedades , Evaluación Preclínica de Medicamentos/métodos , Femenino , Peróxido de Hidrógeno/metabolismo , Leptina/deficiencia , Recuento de Leucocitos , Pulmón/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Obesos , Infiltración Neutrófila/inmunología , Fagocitosis/efectos de los fármacos , Fagocitosis/inmunología , Neumonía Neumocócica/inmunología , Neumonía Neumocócica/microbiología , Streptococcus pneumoniae/aislamiento & purificación , Análisis de SupervivenciaRESUMEN
An attempt has been made to replace antibiotics by chlorophyllypt (0.25 per cent solution in physiological sodium chloride solution administered by intravenous drip). The clinical, laboratory and X-ray parameters in 22 patients treated by this drug normalized in earlier terms than those in 19 patients who received the traditional antibiotic therapy. Chlorophyllypt was found to have the immunocorrective effect manifested by the normalization of the T-lymphocyte number and their theophylline-resistant subpopulation. No such an effect was achieved when broad-action antibiotics were used.
Asunto(s)
Clorofila/uso terapéutico , Extractos Vegetales/uso terapéutico , Neumonía Neumocócica/tratamiento farmacológico , Neumonía Estafilocócica/tratamiento farmacológico , Enfermedad Aguda , Adyuvantes Inmunológicos/inmunología , Adulto , Anciano , Ensayos Clínicos como Asunto , Combinación de Medicamentos/uso terapéutico , Femenino , Humanos , Inmunoglobulinas/análisis , Recuento de Leucocitos/efectos de los fármacos , Masculino , Persona de Mediana Edad , Neumonía Neumocócica/inmunología , Neumonía Estafilocócica/inmunología , Formación de Roseta , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunologíaRESUMEN
To evaluate the influence of vitamin C on pulmonary antibacterial mechanisms, normal CD-1 mice were administered sodium ascorbate (200 mg/kg/24 h) and challenged intratracheally with type 3 Streptococcus pneumoniae. Survival rates were similar in ascorbate-treated and control animals. When infected with a high inoculum (1 X 10(6) cfu), animals given vitamin C demonstrated a significant enhancement in their capacity to clear viable pneumococci from the lungs at 24 h after challenge; the augmented pulmonary clearance was associated with an increased influx of granulocytes at 6 and 24 h. After infection with a lower inoculum (1 X 10(5) cfu), animals treated with the vitamin exhibited a significant advantage in pulmonary clearance and granulocyte recruitment but at 6 h only. After a very low inoculum challenge (1 X 10(4) cfu), the clearance of viable pneumococci was retarded in ascorbate-treated mice. In vitro, the pneumococcidal capacity of resident alveolar macrophages from animals given vitamin C was significantly reduced, but the ability of these cells to generate leukocyte chemoattractant activity after stimulation with the calcium ionophore A23187 remained unaltered. We conclude that in the mouse, large doses of vitamin C alter pulmonary defense mechanisms against S. pneumoniae; however, these changes do not appear to convey a substantial advantage to the host.